---
title: "China's Drug Regulator Puts Hengrui Pharmaceuticals' SHR-1918 Injection in Priority Review"
description: "China's Drug Regulator Puts Hengrui Pharmaceuticals' SHR-1918 Injection in Priority Review"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276838200.md"
published_at: "2026-02-25T05:42:03.000Z"
---

# China's Drug Regulator Puts Hengrui Pharmaceuticals' SHR-1918 Injection in Priority Review

### Related Stocks

- [600276.CN - Hengrui Pharma](https://longbridge.com/en/quote/600276.CN.md)
- [513060.CN - Bosera Hang Seng Health Care ETF(QDII)](https://longbridge.com/en/quote/513060.CN.md)
- [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md)
- [01276.HK - HENGRUI PHARMA](https://longbridge.com/en/quote/01276.HK.md)
- [516820.CN - Ping An CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/516820.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 诺和诺德 UBT251 在华二期临床数据亮眼，减重效果近 20% | 诺和诺德授权药 UBT251 中国二期临床数据亮眼：用药 24 周体重最高减 19.7%（安慰剂仅 2%），公司称 “非常受鼓舞”。但受 Cagrisema 负面消息拖累，股价仍跌超 4%。诺和诺德已支付 2 亿美元首付款，总交易或达 20 | [Link](https://longbridge.com/en/news/276728466.md) |
| Palumbo Wealth Management LLC 购入了 ProShares Ultra Nasdaq Biotech $BIB 的新股权 | Palumbo Wealth Management LLC 在第三季度收购了 ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) 的新股份，购买了 12,851 股，价值约为 766,000  | [Link](https://longbridge.com/en/news/276735169.md) |
| 了解美容注射的局限性以及何时选择面部提升手术，Nicole Schrader 博士为您解答 | 尼科尔·施雷德博士讨论了面部年轻化中美容注射剂的局限性以及何时考虑进行面部提升。虽然注射剂对年轻患者早期衰老迹象有效，但随着衰老的进展，它们可能无法提供理想的效果。最终，像面部提升这样的外科选项可以通过重新定位基础组织，提供更可预测和持久的 | [Link](https://longbridge.com/en/news/276776925.md) |
| 中国医药系统的特应性皮炎药物获得中国批准 | 中国医疗系统获得特应性皮炎药物的中国批准 | [Link](https://longbridge.com/en/news/276718382.md) |
| 上海复星医药旗下子公司在中国获得肺癌药物的试验许可 | 上海复星医药子公司获得中国肺癌药物临床试验批准 | [Link](https://longbridge.com/en/news/276886600.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.